| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | |||||||||
Net loss | |||||||||
-19,352 | -16,168 | 22,228 | -33,309 | -81,010 | -55,466 | -39,485 | -66,369 | -56,582 | -19,397 |
Income from discontinued operations | |||||||||
- | - | 38,399 | -2,051 | - | - | - | -30,267 | -22,016 | 6,412 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Share-based compensation | |||||||||
1,295 | 2,453 | 1,963 | 1,773 | 9,750 | 11,209 | 6,838 | 6,712 | 10,266 | 7,863 |
Depreciation and amortization | |||||||||
65 | 225 | 372 | 450 | 2,686 | 2,186 | 1,605 | 1,550 | 1,440 | 137 |
Amortization of preferred stock discount and issuance cost | |||||||||
- | - | - | - | - | - | - | 1,609 | 2,440 | 281 |
Changes in fair value of derivative liability | |||||||||
- | - | - | - | - | 23 | 77 | 373 | 2,096 | -138 |
Changes in acquisition-related contingent consideration | |||||||||
- | - | - | - | -18,260 | -3,080 | 1,900 | 4,420 | - | - |
Impairment of goodwill and intangible assets | |||||||||
- | - | - | - | 62,273 | - | - | - | - | - |
Gain on disposal of assets | |||||||||
0 | 1,429 | -212 | -591 | 0 | - | - | - | - | - |
Income tax benefit | |||||||||
- | - | 11,526 | 0 | 17,243 | 104 | -780 | 175 | - | - |
Deferred income taxes | |||||||||
- | - | -575 | 0 | - | - | - | - | - | - |
Impairment of Intangible Assets, Finite-lived | |||||||||
- | - | - | - | - | 0 | 0 | - | - | - |
Changes in acquisition-related contingent consideration | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Write off of acquired in-process research and development | |||||||||
- | - | - | - | - | - | - | - | 1,150 | 0 |
Loss on disposal of assets | |||||||||
- | - | - | - | - | - | - | -13 | 0 | - |
Bad debt recovery | |||||||||
- | - | - | - | - | -6 | -234 | 511 | - | - |
Loss on disposal of assets | |||||||||
- | - | - | - | - | - | - | - | - | -3 |
Gain on contract termination | |||||||||
- | - | - | - | - | - | - | - | - | 656 |
Contributions paid with common stock | |||||||||
- | - | - | - | - | - | - | - | 607 | 0 |
Bad debt recovery | |||||||||
- | - | - | - | - | - | - | - | 87 | -39 |
Amortization/accretion on marketable securities | |||||||||
232 | 282 | 340 | 0 | 95 | 51 | 0 | 0 | - | - |
Goodwill impairment charge | |||||||||
- | - | - | - | - | - | - | - | - | 558 |
Changes in operating assets and liabilities: | |||||||||
Deferred income taxes | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Prepaid and other current assets | |||||||||
-238 | -261 | -1,014 | -457 | -872 | 2,768 | 758 | 178 | 350 | 221 |
Accounts receivable | |||||||||
- | - | - | 101 | -545 | 1,198 | 573 | 554 | 443 | -59 |
Deferred costs | |||||||||
- | - | - | - | 344 | 1,296 | 157 | 465 | 647 | 0 |
Unearned revenues | |||||||||
- | - | - | - | 1,011 | 2,517 | 348 | 178 | 948 | 60 |
Other assets | |||||||||
-504 | -291 | -148 | -222 | -286 | -613 | 204 | -2,414 | -53 | 127 |
Due to PCT | |||||||||
- | - | 1,682 | -2,784 | - | - | - | - | - | - |
Accounts payable, accrued liabilities and other liabilities | |||||||||
-1,864 | -5,901 | 5,667 | -3,145 | 79 | 469 | 2,916 | 1,677 | -486 | -1,004 |
Net cash used in operating activities - continuing operations | |||||||||
- | - | -20,238 | -28,225 | - | - | - | -18,759 | -21,773 | -18,677 |
Net cash used in operating activities - discontinued operations | |||||||||
- | - | -638 | 4,557 | - | - | - | 4,907 | 845 | 10,200 |
Net cash used in operating activities | |||||||||
-18,882 | -19,986 | -20,876 | -23,667 | -39,258 | -46,895 | -27,101 | -13,852 | -20,927 | -8,476 |
Cash flows from investing activities: | |||||||||
Purchase of marketable securities | |||||||||
32,938 | 69,690 | 60,158 | 0 | 6,081 | 8,043 | 0 | 0 | - | - |
Sale of marketable securities | |||||||||
54,370 | 62,567 | 33,873 | 0 | 13,066 | 913 | 0 | 0 | - | - |
Proceeds from CFC device sale | |||||||||
0 | 2,550 | 0 | - | - | - | - | - | - | - |
Cash Acquired from Acquisition | |||||||||
- | - | - | - | - | 50 | 0 | 0 | 320 | 0 |
Proceeds from PCT sale | |||||||||
- | - | 74,607 | 0 | - | - | - | 12,280 | 0 | - |
Net cash sold in PCT sale | |||||||||
- | - | 6,727 | 0 | - | - | - | - | - | - |
Change in restricted cash used as collateral for notes payable | |||||||||
- | - | - | - | - | - | - | - | -2 | 2,500 |
Acquisition of property and equipment | |||||||||
0 | 134 | 135 | 1,099 | 3,185 | 3,657 | 2,691 | 531 | 574 | 1,095 |
Net cash (used in) provided by investing activities - continuing operations | |||||||||
- | - | 41,460 | -1,099 | - | - | - | 11,748 | -251 | -3,595 |
Net cash used in investing activities - discontinued operations | |||||||||
- | - | -189 | -1,749 | - | - | - | -5,660 | -1,803 | -13,510 |
Net cash provided by investing activities | |||||||||
21,432 | -4,707 | 41,271 | -2,849 | 3,798 | -10,736 | -2,691 | 6,088 | -2,054 | -17,105 |
Cash flows from financing activities: | |||||||||
Proceeds from exercise of options | |||||||||
0 | 355 | 13 | 0 | - | 271 | 150 | 0 | 7 | - |
Tax withholding payments on net share settlement equity awards | |||||||||
130 | 403 | 358 | 72 | 0 | - | - | - | - | - |
Net proceeds from the exercise of options and warrants | |||||||||
- | - | - | - | - | - | - | - | - | 3,101 |
Net proceeds from issuance of common stock | |||||||||
1,313 | 1,031 | 5,702 | 11,560 | 36,471 | 16,710 | 58,736 | 16,428 | 21,152 | 21,212 |
Repayment of long-term debt | |||||||||
- | - | 5,651 | 9,348 | 0 | - | - | - | - | - |
Proceeds from long term debt | |||||||||
- | - | - | - | - | 15,000 | 0 | 0 | - | - |
Debt issuance costs | |||||||||
- | - | - | - | - | 523 | 0 | 0 | - | - |
Net proceeds from issuance of preferred stock | |||||||||
- | - | - | - | - | - | - | - | - | 8,894 |
Payment from related party | |||||||||
- | - | - | - | - | - | - | - | - | 175 |
Repayment of mortgage loan | |||||||||
- | - | - | - | - | 3,236 | 201 | 196 | 149 | 0 |
Proceeds from notes payable | |||||||||
- | - | 401 | 803 | 1,087 | 1,827 | 1,041 | 666 | 149 | 431 |
Repayment of notes payable | |||||||||
0 | 159 | 965 | 1,030 | 954 | 1,097 | 503 | 440 | 180 | -314 |
PCT dividend to Caladrius | |||||||||
- | - | - | 15,000 | - | - | - | - | - | - |
Repayment of debt to related party | |||||||||
- | - | - | - | - | - | - | - | 3,000 | 0 |
Repayment of preferred stock | |||||||||
- | - | - | - | - | - | - | 5,394 | 650 | 0 |
Payment of dividend for preferred stock | |||||||||
- | - | - | - | - | - | - | 327 | 0 | -222 |
Sale of ownership interest in subsidiary | |||||||||
- | - | - | - | 0 | 0 | 62 | 228 | 0 | - |
Net cash provided by (used in) financing activities - continuing operations | |||||||||
- | - | -858 | 16,912 | - | - | - | 17,111 | 17,329 | 33,278 |
Net cash used in financing activities - discontinued operations | |||||||||
- | - | -74 | 3,990 | - | - | - | -8,370 | 2,739 | 576 |
Net cash (used in) provided by financing activities | |||||||||
1,183 | 824 | -932 | 20,903 | 36,604 | 30,672 | 62,189 | 8,741 | 20,069 | 33,855 |
Net increase in cash and cash equivalents | |||||||||
3,733 | -23,869 | - | - | - | - | - | - | - | - |
Net (decrease) increase in cash, cash equivalents and restricted cash | |||||||||
- | - | 19,463 | -5,613 | - | - | - | - | - | - |
Impact of changes of foreign exchange rates | |||||||||
- | - | - | - | - | - | - | 14 | 46 | 180 |
Net increase (decrease) in cash and cash equivalents | |||||||||
- | - | - | - | 1,144 | -26,959 | 32,396 | 992 | -2,866 | 8,453 |
Supplemental Disclosure of Cash Flow Information: | |||||||||
Interest | |||||||||
0 | 5 | 712 | - | - | - | - | - | - | - |
Interest | |||||||||
- | - | - | 1,823 | 1,497 | 232 | 274 | 1,771 | 1,522 | 279 |
Proceeds from exercise of warrants | |||||||||
- | - | - | - | - | 1,720 | 3,028 | 6,604 | 0 | - |
Taxes | |||||||||
0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,100 | 1,119 | 2,056 |
Acquisition of property and equipment | |||||||||
- | - | - | - | - | - | - | - | - | 2,443 |
Capitalized interest | |||||||||
- | - | - | - | - | - | - | 182 | 384 | 391 |
Common stock, warrants and options received upon sale of Erye | |||||||||
- | - | - | - | - | - | - | 1,117 | 0 | - |
Common stock and contingent consideration issued in merger | |||||||||
- | - | - | - | - | 33,490 | 0 | - | - | - |
Common stock, warrants and contingent consideration issued with the acquisition of Amorcyte | |||||||||
- | - | - | - | - | - | - | - | 8,483 | - |
Common stock and warrants issued with the acquisition of PCT | |||||||||
- | - | - | - | - | - | - | - | 17,200 | 0 |
Common stock issued pursuant to the redemption of Convertible Redeemable Series E 7% Preferred Stock | |||||||||
- | - | - | - | - | - | - | 1,026 | 3,511 | 0 |
Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock | |||||||||
- | - | - | - | - | - | - | 175 | 748 | 0 |
Financing costs for capital stock raises | |||||||||
- | - | - | - | - | - | - | - | - | 33 |
Conversion of Convertible Redeemable Series C Preferred Stock | |||||||||
- | - | - | - | - | - | - | - | - | 13,720 |
Dividend to related party reinvested as loan payable | |||||||||
- | - | - | - | - | - | - | - | 11,726 | 0 |